D&D Pharmatech (XKRX:347850) ROCE % : 1.94% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. D&D Pharmatech's annualized ROCE % for the quarter that ended in Dec. 2023 was 1.94%.

D&D Pharmatech ROCE % Historical Data

The historical data trend for D&D Pharmatech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech ROCE % Chart

D&D Pharmatech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

22.17

-42.79

-35.14

-144.01

10.72

D&D Pharmatech Quarterly Data
	Dec22	Sep23	Dec23
ROCE %	-1,215.38	-	1.94

D&D Pharmatech ROCE % Calculation

D&D Pharmatech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	5921.289	/	( ( (93641.563 - 54922.551)	+	(79203.645 - 7486.586) )	/ 2 )
	=	5921.289	/	( (38719.012	+	71717.059)	/ 2 )
	=	5921.289	/	55218.0355
	=	10.72 %

D&D Pharmatech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1408.428	/	( ( (81260.875 - 7676.483)	+	(79203.645 - 7486.586) )	/ 2 )
	=	1408.428	/	( ( 73584.392	+	71717.059 )	/ 2 )
	=	1408.428	/	72650.7255
	=	1.94 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

D&D Pharmatech (XKRX:347850) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

D&D Pharmatech ROCE % Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech (XKRX:347850) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech (XKRX:347850) Headlines

No Headlines